Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Archives of Neurology|January 21, 2004
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trialsMichael Grundman, Ronald C Petersen, Steven H Ferris, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 14, 2022
A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease TrialEric M Reiman, Jeremy J Pruzin, Silvia Rios-Romenets, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 24, 2025
Effects of exercise on cognition and Alzheimer's biomarkers in a randomized controlled trial of adults with mild cognitive impairment: The EXERT studyLaura D Baker, Judy A Pa, Jeffrey A Katula, et al.
Neuroimage. Clinical|July 12, 2021
PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriersValentina Ghisays, Francisco Lopera, Dhruman D Goradia, et al.
Brain Communications|March 26, 2026
Pontine pathology mediates common symptoms of blast-induced chronic mild traumatic brain injuryJames S Meabon, Abigail G Schindler, Daniel R Murray, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 1, 2022
Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia TrialClara Vila-Castelar, Pierre N Tariot, Kaycee M Sink, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 18, 2020
Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia TrialSilvia Rios-Romenets, Francisco Lopera, Kaycee M Sink, et al.
The Lancet. Neurology|January 24, 2026
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trialPierre N Tariot, Francisco S Lopera, Silvia Ríos-Romenets, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 21, 2012
Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humansTrygve E Bakken, J Cooper Roddey, Srdjan Djurovic, et al.
Pageof 9